Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park

Clin Mol Hepatol. 2021;27(1):144-156. Published online December 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0095

View: 7543 Download: 285 Web of Science: 19 Crossref: 19

Jae Eun Park, M.D., Chang Hyeong Lee, M.D., Byung Seok Kim, M.D., Im Hee Shin, Ph.D.

Clin Mol Hepatol. 2010;16(1):66-74. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.66

View: 4710 Download: 90 Crossref: 7

Young Seok Lim,Hyo Suk Lee,Jung Hwan Yoon,Jin Suk Han,Chung Yong Kim

Clin Mol Hepatol. 2000;6(1):12-23. Published online January 1, 2000

View: 2841 Download: 32

1 |

Viewed By 5875	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5221	MAFLD: How is it different from NAFLD?
Viewed By 4947	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4028	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4011	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 137	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 104	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 82	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 71	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 63	MAFLD: How is it different from NAFLD?

Search